9 37

Cited 0 times in

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

DC Field Value Language
dc.contributor.author정현철-
dc.date.accessioned2022-11-24T00:28:34Z-
dc.date.available2022-11-24T00:28:34Z-
dc.date.issued2021-11-
dc.identifier.issn1436-3291-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190695-
dc.description.abstractBackground: In the primary analysis population (i.e., PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient population. We present results of prespecified health-related quality of life (HRQoL) analyses. Methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ gastric cancer questionnaire (QLQ-STO22), and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L). Data were analyzed from patients who received ≥ 1 dose of study treatment and who completed ≥ 1 HRQoL assessment. Key analyses included baseline to week 12 least-squares mean (LSM) change in global health status (GHS)/QoL, functional/symptom subscales, and time to deterioration (TTD; ≥ 10-point decrease from baseline) for specific subscales. Results: The HRQoL population included 371 patients (pembrolizumab, n = 188; paclitaxel, n = 183). Compliance and completion rates for all 3 questionnaires were similar in both groups at baseline and week 12. There was no difference in LSM change between groups (- 3.54; 95% CI - 8.92 to 1.84) in GHS/QoL at week 12. LSM change from baseline to week 12 for most QLQ-C30, QLQ-STO22, and EQ-5D-3L subscales indicated some worsening of QoL in both groups. TTD for GHS/QoL, nausea/vomiting, and appetite loss subscales in QLQ-C30 and the pain subscales in QLQ-STO22 were similar between treatment groups. Conclusions: In this population with advanced gastric and GEJ cancer receiving second-line treatment, HRQoL was similar in patients receiving pembrolizumab and those receiving paclitaxel. Clinical trial registry and number: ClinicalTrials.gov, NCT02370498.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherSpringer-Verlag Tokyo-
dc.relation.isPartOfGASTRIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Monoclonal, Humanized / administration & dosage-
dc.subject.MESHAntibodies, Monoclonal, Humanized / therapeutic use*-
dc.subject.MESHAntineoplastic Agents, Immunological / administration & dosage-
dc.subject.MESHAntineoplastic Agents, Immunological / therapeutic use*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBelgium-
dc.subject.MESHEsophagogastric Junction*-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHProgression-Free Survival-
dc.subject.MESHQuality of Life-
dc.subject.MESHStomach Neoplasms / drug therapy*-
dc.subject.MESHStomach Neoplasms / mortality-
dc.subject.MESHStomach Neoplasms / pathology-
dc.subject.MESHSurveys and Questionnaires-
dc.titleHealth-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorEric Van Cutsem-
dc.contributor.googleauthorMayur Amonkar-
dc.contributor.googleauthorCharles S Fuchs-
dc.contributor.googleauthorMaria Alsina-
dc.contributor.googleauthorMustafa Özgüroğlu-
dc.contributor.googleauthorYung-Jue Bang-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorKei Muro-
dc.contributor.googleauthorEray Goekkurt-
dc.contributor.googleauthorAl B Benson 3rd-
dc.contributor.googleauthorWeijing Sun-
dc.contributor.googleauthorZev A Wainberg-
dc.contributor.googleauthorJosephine M Norquist-
dc.contributor.googleauthorXinqun Chen-
dc.contributor.googleauthorChie-Schin Shih-
dc.contributor.googleauthorKohei Shitara-
dc.identifier.doi10.1007/s10120-021-01200-w-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ00916-
dc.identifier.eissn1436-3305-
dc.identifier.pmid34363528-
dc.subject.keywordChemotherapy-
dc.subject.keywordGastric cancer-
dc.subject.keywordHRQoL-
dc.subject.keywordPembrolizumab-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthor정현철-
dc.citation.volume24-
dc.citation.number6-
dc.citation.startPage1330-
dc.citation.endPage1340-
dc.identifier.bibliographicCitationGASTRIC CANCER, Vol.24(6) : 1330-1340, 2021-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.